ClinicalTrials.gg
CompletedNCT05124717Updated Nov 18, 2021

Fed Bioequivalence Study of 2 Metformin 500 mg Prolongued Release Tablets in 28 Healthy Male and Female Volunteers

A Phase 1 interventional study of Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine) and Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK) in Pharmacokinetics, sponsored by Joint Stock Company "Farmak". Completed at 1 site in Czechia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-18.

Sponsored by Joint Stock Company "Farmak" · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Jun 2019, registered Nov 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of the study is to compare the bioavailability of the Test and Reference products both containing Metformin 500 mg prolonged release tablets (MFM) in healthy male and female volunteers under fed conditions and to assess the bioequivalence of these products based on confidence acceptance intervals of 80.00% to 125.00% for AUC(o-t)and Cmax of MFM as primary endpoints.

Read the detailed description

An Open, Comparative, Randomized, Crossover Clinical Trial to Evaluate the Bioequivalence of Single Doses of Test Product Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine) and Reference Product Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK) in Healthy, Adult Male and Female Subjects Under Fed Conditions Single oral dose of Glucophage® XR 500 mg prolonged release tablets of Reference product or Metformin, prolonged-release tablets 500 mg of Test product will be administered to volunteers under fed conditions in the morning of Day 1 of each Study Period.

Pharmacokinetic parameters of MFM were calculated from plasma concentrations determined by validated HPLC/MS/MS method.

Pharmacokinetic parameters of the Test and Reference tablets were compared.

During each period 21 samples were taken: prior to dosing (-1.0) and 1.0, 2.0, 3.0, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 10.0, 12.0, 16.0, 24.0, 32.0 and 36.0 hours after IMP administration in each study period.

The study consists of two study periods with a washout period of at least 7 days between doses.

Adverse events and clinically significant deviations from laboratory tests, physical examinations and vital signs were reported for the evaluation of safety.

02

Conditions studied

  • Pharmacokinetics

Keywords

  • bioequivalence
  • pharmacokinetics
  • generic drugs
  • Metformin 500 mg Prolonged Release Tablets
  • Prolonged Release Tablets
  • oral dosage form
  • Metformin
03

In context

Lead sponsor

Joint Stock Company "Farmak" is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and non-pregnant and no breast-feeding females (must have a negative pregnancy test result prior to dosing). Caucasian race.
  • Non-smoker or past-smoker (who has stopped smoking at least 6 months before the first dosing).
  • (BMI) 18.5 to 30.0 kg/m2, inclusive and body weight between 50 kg and 100 kg(on the day of screening).
  • Subject was available for the whole study and has provided his/her written .
  • Subjects in good health, as determined by screening medical history, physical examination, vital signs assessments (pulse rate, systolic and diastolic blood pressure, and body temperature) and 12-lead (ECG). Minor deviations outside the reference ranges were acceptable, if were deemed not by the Investigator.
  • Subjects in good health and with glucose between 3.3 mmol/L-5.5 mmol/l at screening, as determined by screening clinical laboratory evaluations. Minor deviations outside the reference ranges were acceptable, if were deemed not clinically significant by the Investigator.
  • Acceptance of use of measures during the whole study by both female and male subjects.

Exclusion criteria

Exclusion Criteria:

  • Known cardiovascular disease, history of hypotension.
  • Factors in the subject's history that may predispose to ketoacidosis (including pancreatic insulin deficiency, history of pancreatitis, caloric restriction disoroders, restricted food intake, alcohol abuse)
  • Gastrointestinal, renal or hepatic diseases and/or pathological findings present or in history, which might interfere with the drug pharmacokinetics.
  • Previous liver disease or elevations in serum transaminases (ALT) or aspartate aminotransferase (AST) ≥1.0 (ULN) at the screening (for women 0-0.52 µmol/L and for men 0-0.68 µmol/L).
  • Acute or chronic diseases and/or clinical finding which may interfere with the aims of the study or with the drug's safety, tolerability, bioavailability and/or pharmacokinetics of the Medicinal Product (IMP).
  • History of kidney disease and with impaired renal function.
  • History of severe allergy or allergic reactions to the study IMP, its or related drugs.
  • illness within 28 days before the first dosing, including major surgery.
  • Any significant clinical abnormality including surface antigen (HBsAg), virus (HCV), and / or () HIV. (On screening)
  • Positive result of blood pregnancy test at screening or positive urine pregnancy test at check-in or breast-feeding or lack of results of pregnancy test.
  • Positive results of drugs of abuse in urine at screening and at check-in.
  • Positive result of alcohol breath test at screening and at check-in.
  • Positive result of urine cotinine test at screening.
  • Serious mental disease and/or inability to cooperate with clinical team.
  • Sitting blood pressure after a minimum of 5 minutes of rest is out of the range of 90-140 mmHg for systolic blood pressure (BP) and/or 60-90 mmHg for diastolic BP and/or heart rate out of the range of 50-100 bpm during the screening procedure.
  • Body ear temperature is out of the range of 35.7-37.6°C at screening.
  • Orthostatic hypotension during the screening procedure.
  • Drug, alcohol (of ≥40 g per day pure ethanol), solvents or caffeine abuse.
  • Use of organ-toxic drugs or systemic drugs known to substantially alter liver metabolism within 90 days before the first dosing.
  • Use of any prescription medication for a period of 28 days before the first dosing.
  • Use of any OTC (over-the-counter) medication including vitamins, herbal medications and food supplements less than 14 days before the first dosing.
  • Getting a tattoo, body piercing or any cosmetic treatment involving skin piercing within 90 days before the screening unless evaluated by Investigator as non-significant for inclusion in the study.
  • Donation or loss of at least 500 mL of blood within 90 days or donation of plasma or within 14 days before the first dosing.
  • Anaemia, below 120 g/L for women and 130 g/L for men at screening.
  • Less than 30 days between exit procedure in previous study and the first dosing in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Treatment A

    Test Product Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)

    Drug: Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)

  • Active comparator
    Treatment B

    Reference Product Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)

    Drug: Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)

Interventions

  • DrugMetformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)

    One tablet of the Test product was administered orally with 240 mL of water.

    Also known as: Diaformin® SR 500mg tablets (JSC Farmak, Ukraine), Diabufor® XR 500mg tablets (JSC Farmak, Ukraine)

  • One tablet of the Reference product was administered orallyn with 240 mL of water.

    Also known as: Glucophage® XR 500 mg

06

What researchers measure

Primary outcomes

  1. AUC(0-t)

    area under the plasma drug concentration versus time curve

    Time frame: up to 36 hours post-administration

  2. Cmax

    maximum plasma concentration observed

    Time frame: up to 36 hours post-administration

Secondary outcomes

  1. AUC(0-∞)

    area under the plasma drug concentration versus time curve from time zero to infinity

    Time frame: up to 36 hours post-administration

  2. AUC(0-12h)

    the area under the plasma drug concentration versus time curve calculated from time zero to time 12 hours after dosing

    Time frame: from time zero to time 12 hours after dosing.

  3. AUC(12h-t)

    the area under the plasma drug concentration versus time curve calculated from time 12 hours after dosing to time of the last sample above LLOQ.

    Time frame: 12 hours after dosing up to 36 hours post-administration

  4. AUC(0-24h)

    the area under the plasma drug concentration versus time curve calculated from time zero to time 24 hours after dosing.

    Time frame: from time zero to time 24 hours after dosing.

  5. tmax

    the time of the maximum plasma drug concentration.

    Time frame: up to 36 hours post-administration

  6. λz

    apparent first-order elimination

    Time frame: up to 36 hours post-administration

  7. AUCres

    Residual area

    Time frame: up to 36 hours post-administration

07

Study locations

1 site
  • QUINTA-ANALYTICA s.r.o.
    Prague, 10200, Czechia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Jul 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2021
First posted
Nov 18, 2021
StartActual
Jun 25, 2019
Primary completionActual
Jul 3, 2019
CompletionActual
Jul 3, 2019
Last update
Nov 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05124717
Lead sponsor
Joint Stock Company "Farmak"
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
Jun 25, 2019
Primary completion
Jul 3, 2019
Completion
Jul 3, 2019
Last update
Nov 18, 2021

Study contacts

Vlad Udovytskyi
study chair · Joint Stock Company "Farmak"

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion